MATRIXYL - Research Grade Peptide

MATRIXYL – Research-Grade Palmitoylated Pentapeptide

For research purposes only. This product is supplied exclusively for scientific laboratory research and analytical purposes. It is not intended for human or animal use, consumption, clinical use or therapeutic application. It must not be used in any way that contravenes applicable laws or the requirements of the Medicines and Healthcare products Regulatory Agency.

• Research-grade Palmitoyl Pentapeptide-4 laboratory material with batch documentation available where supplied
• Defined KTTKS pentapeptide sequence containing an N-terminal palmitoyl modification
• Supplied as measured dry or lyophilised laboratory material in sealed flip-top headspace vials
• Batch identity, chromatographic purity, lipopeptide content and analytical specifications stated in the applicable Certificate of Analysis
• Handled and supplied exclusively as a research-use laboratory material

MATRIXYL, as identified in this product listing, refers to Palmitoyl Pentapeptide-4: a synthetic lipopeptide comprising the pentapeptide sequence Lys-Thr-Thr-Lys-Ser modified with an N-terminal palmitoyl group. Each vial contains measured laboratory material prepared to support controlled scientific handling, storage and analytical investigation. The stated nominal amount refers to the declared Palmitoyl Pentapeptide-4 content of a single vial, subject to the applicable batch documentation. Where dissolution is required, the solvent, concentration, handling procedure and storage conditions stated in the applicable Certificate of Analysis, Safety Data Sheet or validated laboratory method should be followed. We do not provide advice or recommendations concerning dosage, administration or use in humans or animals.

Chemical and Structural Information:

• Product Name: MATRIXYL
• Preferred Substance Name: Palmitoyl Pentapeptide-4
• Alternative Names: Matrixyl; Pal-KTTKS; Palmitoyl Pentapeptide-3; Palmitoyl Pentapeptide; Lipopentapeptide 3
• Material Classification: Synthetic N-palmitoylated pentapeptide and lipopeptide
• Peptide Sequence Length: Five amino-acid residues
• Core Peptide Sequence: Lys-Thr-Thr-Lys-Ser
• One-Letter Sequence: KTTKS
• Complete Structural Shorthand: Pal-Lys-Thr-Thr-Lys-Ser-OH
• N-Terminal Modification: The N-terminal lysine residue is acylated with a hexadecanoyl or palmitoyl group
• C-Terminal Structure: Free serine carboxylic acid terminus
• Systematic Chemical Name: N²-(1-oxohexadecyl)-L-lysyl-L-threonyl-L-threonyl-L-lysyl-L-serine
• CAS Number: 214047-00-4
• PubChem Compound Identifier: CID 9897237
• Unique Ingredient Identifier: KK181SM5JG
• European Community Number: 606-757-9
• Molecular Formula: C₃₉H₇₅N₇O₁₀
• Average Molecular Weight: Approximately 802.05 g/mol
• InChIKey: WSGCRSMLXFHGRM-DEVHWETNSA-N
• Formula Basis: The molecular formula and molecular weight describe the uncountered Palmitoyl Pentapeptide-4 molecular structure without formulation excipients, residual water, counter-ions or solvates
• Physical Form: Dry powder or lyophilised laboratory material, as stated in the applicable batch Certificate of Analysis
• Appearance: White to off-white laboratory material, subject to confirmation in the applicable batch Certificate of Analysis
• Product-Identity Clarification: This listing describes the single Palmitoyl Pentapeptide-4 substance corresponding to CAS number 214047-00-4 and should not be interpreted as describing an unspecified multi-ingredient peptide blend
• Purity Specification: The applicable chromatographic purity result, analytical method and acceptance criterion are stated in the batch Certificate of Analysis
• Lipopeptide-Content Specification: Net Palmitoyl Pentapeptide-4 content should be distinguished from chromatographic purity and interpreted alongside water, counter-ion, residual-solvent and formulation results
• Palmitoylation Confirmation: Product identity should confirm the presence and position of the N-terminal palmitoyl modification using suitable mass-spectrometry or equivalent analytical data
• Peptide Sequence Confirmation: The KTTKS peptide sequence and terminal structures should be confirmed using the applicable supplier and batch records
• Chemical-Form Confirmation: The applicable Certificate of Analysis should identify whether the supplied material is the uncountered lipopeptide, an acetate form, a trifluoroacetate form or another counter-ion or solvate form
• Counter-Ion Confirmation: Acetate, trifluoroacetate or another counter-ion may affect the total measured material mass and net lipopeptide content of the supplied laboratory material
• Residual-Solvent Specification: Applicable residual solvents arising from peptide synthesis, cleavage, palmitoylation and chromatographic purification should be stated or controlled through the batch specification
• Related-Impurity Control: Unmodified KTTKS, incompletely synthesised peptide sequences, deletion sequences, unreacted palmitic acid and other acylation-related or process-related impurities are separate quality attributes
• Endotoxin Specification: The applicable bacterial endotoxin or LPS result, analytical method, reporting units, method-suitability controls and acceptance criterion should be stated in the batch Certificate of Analysis
• Analytical Interpretation: Molecular identity, peptide sequence, palmitoylation status, chromatographic purity, net lipopeptide content, aggregation, water content, residual solvent content, counter-ion content and bacterial endotoxin results are separate analytical measurements and should be interpreted together

✓ Batch documentation – Completed Certificate of Analysis documentation is provided where supplied for review.
✓ Certificate of Analysis – Accessible through the product QR code where provided for the applicable batch.
✓ Safety Data Sheet – Supplied to support appropriate laboratory handling, storage and regulatory compliance.
✓ Sequence documentation – The KTTKS pentapeptide sequence and terminal structures should be confirmed using the applicable batch records.
✓ Palmitoylation documentation – The N-terminal palmitoyl modification should be supported by appropriate molecular-identity data.
✓ Mass-spectrometry documentation – Molecular identity should be supported by analytical mass data consistent with the specified Palmitoyl Pentapeptide-4 structure.
✓ Purity documentation – The reported chromatographic purity applies only to the analytical method and batch stated in the Certificate of Analysis.
✓ Lipopeptide-content documentation – Net Palmitoyl Pentapeptide-4 content should be distinguished from chromatographic purity and interpreted alongside water, counter-ion and residual-solvent results.
✓ Chemical-form documentation – The uncountered lipopeptide, acetate form, trifluoroacetate form or other chemical form should be identified clearly in the applicable product and batch records.
✓ Bacterial endotoxin documentation – The applicable bacterial endotoxin or LPS result should identify the test method, reporting units, method-suitability controls and acceptance criterion.
✓ Supplier documentation – Reviewed where supporting synthesis, palmitoylation, purification and analytical records are supplied.
✓ Fast, reliable and trackable express delivery – Securely packaged and dispatched using insulated or temperature-managed packaging where required by the applicable transport and storage specification.

For Research Use Only
This product is supplied strictly for scientific research, laboratory analysis and experimental work. It is not intended for human consumption, animal use, clinical use, diagnostic use or any form of therapeutic application.

MATRIXYL Product Overview

Our MATRIXYL research-grade Palmitoyl Pentapeptide-4 is supplied for controlled scientific laboratory investigation, analytical method development, lipopeptide characterisation, high-performance liquid chromatography assessment, mass-spectrometry workflows, formulation studies and reference-material comparison. The material comprises the defined KTTKS pentapeptide sequence modified with an N-terminal palmitoyl group.

The palmitoyl modification substantially changes the physicochemical character of the underlying KTTKS pentapeptide and should therefore be confirmed as part of molecular-identity testing. Product identity, peptide sequence, palmitoylation status, chromatographic purity, net lipopeptide content, molecular form, counter-ion content, water content, residual solvents, aggregation, bacterial endotoxin results and other analytical specifications should be confirmed using the applicable batch Certificate of Analysis.

The CAS number 214047-00-4, molecular formula C₃₉H₇₅N₇O₁₀ and average molecular weight of approximately 802.05 g/mol describe the uncountered Palmitoyl Pentapeptide-4 structure. Where the supplied laboratory material contains acetate, trifluoroacetate, residual water, another counter-ion or formulation excipients, the applicable batch documentation should identify their contribution to the total material mass.

Chromatographic purity should not automatically be interpreted as equivalent to the total net Palmitoyl Pentapeptide-4 content of the vial. Similarly, a bacterial endotoxin or LPS result does not establish sterility, molecular identity, correct palmitoylation, peptide-sequence integrity or the absence of every process-related impurity.

For the majority of routine analytical, formulation, chromatographic and general laboratory work, the Regular MATRIXYL specification remains highly suitable. The premium black-and-gold ULTIMATE MATRIXYL option provides an additional preparative high-performance liquid chromatography purification stage and a more stringent bacterial endotoxin and lipopolysaccharide testing specification for scientific projects requiring enhanced quality-control parameters.

View Certificate of Analysis

View Safety Data Sheet